When was WPD Pharmaceuticals founded?

WPD Pharmaceuticals was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is WPD Pharmaceuticals located?

WPD Pharmaceuticals is headquartered in Warsaw, Poland.

Who is the current CEO of WPD Pharmaceuticals?

Mariusz Olejniczak of WPD Pharmaceuticals.

How many employees does WPD Pharmaceuticals have?

As of May 31, 2026, the latest employee count at WPD Pharmaceuticals is 9.

Is WPD Pharmaceuticals a funded company?

WPD Pharmaceuticals is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Oct 05, 2020.

When was the latest funding round of WPD Pharmaceuticals?

WPD Pharmaceuticals' latest funding was a $***** Grant (prize money) round on Oct 05, 2020, with participation from 0 investor.

Where does WPD Pharmaceuticals rank among its competitors?

WPD Pharmaceuticals ranks 887th amongst 3229 active competitors, of which 1113 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of WPD Pharmaceuticals?

WPD Pharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

WPD Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of biological molecules for the treatment of cancer. The company solution will be based on the use of therapy targeting IL-13RA2 and EphA2 receptors by recombinant proteins IL-13 and Ephrin 1 proteins, conjugated to Pseudomonas and Diphtheria bacteria toxins.

Website: wpdpharmaceuticals.com
Social
Phone Number: +48 **********

Key Metrics

Founded Year

2017

Location

Warsaw, Poland

Stage

Public

Latest Funding Round

Grant (prize money), Oct 05, 2020, $*****

Investors

Vermögensclub

Ranked

887^th among 3229 active competitors

Employee Count

9 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2968 more

Exit Details

Public

View WPD Pharmaceuticals' full profile

WPD Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
WPD PHARMACEUTICALS SP. Z OO CIN: 693186 , Poland, Active	Dec 31, 2016	-	-

WPD Pharmaceuticals got listed on Dec 27, 2019.

Click here to take a look at WPD Pharmaceuticals's IPO in detail

WPD Pharmaceuticals has raised funding over 2 rounds. Its first funding round was on Oct 05, 2020. WPD Pharmaceuticals has 1 institutional investor.

Here is the list of recent funding rounds of WPD Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 05, 2020	3521980	Grant (prize money)	6453604	7120957	1320883	6206283
Oct 05, 2020	3586029	Conventional Debt	1309934	9398917	9342427	7520818

Access funding benchmarks and valuations. Sign up today!

View details of WPD Pharmaceuticals's funding rounds and investors

WPD Pharmaceuticals' employee count trend

WPD Pharmaceuticals has 9 employees as of May 26. Here is WPD Pharmaceuticals's employee count trend over the years:

Employee count trend for WPD Pharmaceuticals

Uncover WPD Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of WPD Pharmaceuticals include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of WPD Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Merck & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Altitude Life Science Ventures ... & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Driehaus, Nextech Invest & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Delos Capital Partners, Pappas Capital & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	AstraZeneca, HHS & 32 others	71/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Avidity Partners, Foresite Capital & 16 others	71/100
887th	WPD Pharmaceuticals 2017, Warsaw (Poland), Public	Developer of biological molecules for the treatment of cancer	-	Vermögensclub	44/100